Immunotherapy of AML.
Alatrash
Gheath
G
Division of Cancer Medicine, University of Texas MD, Anderson Cancer Center, Houston, TX, USA.
Molldrem
Jeffrey J
JJ
D000617:Aminoglycosides / Q000627:therapeutic use; D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D019496:Cancer Vaccines / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D016207:Cytokines / Q000627:therapeutic use; D000079982:Gemtuzumab; D006086:Graft vs Host Disease / Q000209:etiology / Q000517:prevention & control; D020544:Graft vs Leukemia Effect; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects; D006801:Humans; D007167:Immunotherapy; D016233:Immunotherapy, Active; D016219:Immunotherapy, Adoptive; D007694:Killer Cells, Natural / Q000637:transplantation; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy / Q000276:immunology / Q000601:surgery / Q000628:therapy*; D017710:Lymphocyte Transfusion / Q000009:adverse effects; D051379:Mice; D009363:Neoplasm Proteins / Q000037:antagonists & inhibitors / Q000276:immunology; D013602:T-Lymphocytes, Cytotoxic / Q000637:transplantation; D014184:Transplantation, Homologous
D000617:Aminoglycosides; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D019496:Cancer Vaccines; D016207:Cytokines; D009363:Neoplasm Proteins; D000079982:Gemtuzumab